M
MISSION Therapeutics
Therapeutics targeting deubiquitylating enzymes for mitochondrial dysfunction diseases
About MISSION Therapeutics
Mission Therapeutics is a biotech startup that operates in the healthcare industry, specifically in the development of innovative therapies for serious diseases. The company's primary focus is on the development of first-in-class therapeutics that inhibit disease-associated deubiquitylating enzymes (DUBs). DUBs are involved in many disease pathologies, making them attractive therapeutic targets.
Read full description
The company's business model revolves around the development of small molecule DUB inhibitors, which are developed both in-house and in collaboration with partners. These inhibitors are used in the treatment of a variety of serious diseases, including acute kidney injury (AKI), rare mitochondria diseases, neurodegeneration, and fibrosis.
Mission Therapeutics' market includes patients suffering from these serious diseases, as well as healthcare providers and other entities in the medical field who may use or distribute their therapies. The company generates revenue through the sale of these therapies, as well as through partnerships with other entities for the development of new inhibitors.
Recently, the company announced the potential of their experimental drug, MTX325, as a disease-modifying therapy for Parkinson’s Disease, as outlined in a publication in Nature Communications. This is a result of an international research collaboration with Harvard Medical, further demonstrating the company's commitment to advancing scientific research and developing transformative therapies.
In summary, Mission Therapeutics is a pioneering biotech company, translating scientific advances into transformative therapies for serious diseases through the development of DUB inhibitors.
At a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Cambridge, United Kingdom
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 65.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Medical Research, Oncology, Drug Development, Spinout, Biotech and Pharma, uk is8 life sciences, UKSU, UKSU2010, Hard Tech
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Oct 2025 | $13M | $396M | SR One · Roche Venture Fund · Pfizer Ventures · Sofinnova Partners | ↗ |
| GRANTOther financing | Jul 2024 | $5.2M | — | Michael J. Fox Foundation for Parkinson's Research | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for MISSION Therapeutics is 2.6K monthly website visits, up 44.4% over the last three months. MISSION Therapeutics's team declined 7.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
- PVPfizer Ventures
Michael J. Fox Foundation for Parkinson's Research
Series A4 investors entered at this stage
Imperial Innovations
Roche Venture Fund
Sofinnova Partners
SR One
Series B and later4 investors entered at this stage
Woodford Investment Management
IP Group
Schroder Adveq
Rosetta Capital
Other known investors2 additional known investors
Cambridge Enterprise
University of Cambridge
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MISSION Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MISSION Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.